Want to see IN:VIMTALABS full AI Analyst Report?
VIMTALABS Stock Chart & Stats
₹609.25
-₹18.70(-1.83%)
At close: 4:00 PM EST
₹609.25
-₹18.70(-1.83%)
Day’s Range― - ―
52-Week Range₹377.30 - ₹902.85
Previous CloseN/A
Volume71.13K
Average Volume (3M)22.50K
Market Cap
₹26.15B
Enterprise Value₹23.68B
Total Cash (Recent Filing)₹564.64M
Total Debt (Recent Filing)₹67.97M
Price to Earnings (P/E)33.7
Beta1.10
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)17.65
Shares Outstanding44,669,353
10 Day Avg. Volume11,086
30 Day Avg. Volume22,501
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)3.71
Price to Sales (P/S)4.16
P/FCF Ratio34.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.1
Revenue Forecast (FY)₹4.71B
Bulls Say, Bears Say
Bulls Say
Very Conservative Balance SheetNear-zero leverage and rising equity materially reduce financial risk and preserve strategic optionality. Over 2–6 months this supports capacity investments, tendering for larger outsourced projects, and resilience through cyclic demand swings without forcing distressed asset sales or equity raises.
Sustained Healthy ProfitabilityConsistent mid-teens net margins and mid-30% EBITDA margin indicate durable pricing power and operational leverage in lab and clinical services. Such margins provide internal funding for reinvestment, support steady returns to stakeholders, and create a buffer versus cost or price pressure over the medium term.
Robust Revenue Growth TrendOrganic revenue growth above mid-teens reflects strong secular demand for outsourced analytical and clinical services. A fee-for-service model tied to regulated testing and trials produces repeatable, contractable revenue streams that support predictable throughput and long-term client relationships.
Bears Say
Margin VolatilityNotable swings in gross and operating margins suggest sensitivity to service mix, pricing dynamics, and cost absorption. Over months this undermines earnings predictability, complicates capacity planning and budgeting, and increases the risk that temporary margin erosion becomes persistent if mix shifts aren't managed.
Uneven Free Cash FlowIntermittent negative free cash flow and working-capital swings indicate project timing and receivables/capex volatility. This can constrain reinvestment or require external funding during growth phases, limiting the company’s ability to scale smoothly or return cash to shareholders in adverse quarters.
ROE Plateau And Volume DependencyStable mid‑teen ROE without expansion implies limited leverage for higher returns and potential scalability limits. Combined with revenue dependence on project volumes and capacity utilization, this raises cyclicality risk: growth may require capital or operational scaling that won’t automatically lift returns.
Vimta Labs Limited News
VIMTALABS FAQ
What was Vimta Labs Limited’s price range in the past 12 months?
Vimta Labs Limited lowest stock price was ₹377.30 and its highest was ₹902.85 in the past 12 months.
What is Vimta Labs Limited’s market cap?
Vimta Labs Limited’s market cap is ₹26.15B.
When is Vimta Labs Limited’s upcoming earnings report date?
Vimta Labs Limited’s upcoming earnings report date is Aug 14, 2026 which is in 39 days.
How were Vimta Labs Limited’s earnings last quarter?
Vimta Labs Limited released its earnings results on May 06, 2026. The company reported ₹4.726 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.726.
Is Vimta Labs Limited overvalued?
According to Wall Street analysts Vimta Labs Limited’s price is currently Overvalued.
Does Vimta Labs Limited pay dividends?
Vimta Labs Limited pays a Annually dividend of ₹2 which represents an annual dividend yield of 0.16%. See more information on Vimta Labs Limited dividends here
What is Vimta Labs Limited’s EPS estimate?
Vimta Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vimta Labs Limited have?
Vimta Labs Limited has 44,669,353 shares outstanding.
What happened to Vimta Labs Limited’s price movement after its last earnings report?
Vimta Labs Limited reported an EPS of ₹4.726 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.338%.
Which hedge fund is a major shareholder of Vimta Labs Limited?
Currently, no hedge funds are holding shares in IN:VIMTALABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vimta Labs Limited
Vimta Labs Limited provides specialized contract research and analytical testing services, operating both within India and internationally. Their extensive offerings encompass general laboratory analyses, comprehensive food and water quality testing, support for preclinical and clinical research, detailed structural and functional assessments of biological molecules, environmental impact studies, and clinical diagnostic reference laboratory capabilities. The company serves a wide array of industries, including pharmaceuticals, biopharmaceuticals, food production, consumer goods, electronics, electrical equipment, agrochemicals, healthcare, medical devices, and many more. Established in 1984, Vimta Labs Limited is headquartered in Hyderabad, India.
Technical Analysis
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―